866-997-4948(US-Canada Toll Free)

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 56 Pages

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Pipeline Review, H2 2016, provides in depth analysis on Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) targeted pipeline therapeutics.

The report provides comprehensive information on the Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1)
- The report reviews Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) Overview 6
Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Products under Development by Stage of Development 7
Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Products under Development by Therapy Area 8
Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Products under Development by Indication 9
Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Products under Development by Companies 13
Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Companies Involved in Therapeutics Development 22
Arno Therapeutics Inc 22
Nyken BV 23
Oncogenex Pharmaceuticals Inc 24
RESprotect GmbH 25
Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Drug Profiles 26
apatorsen - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
AR-12 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
brivudine - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
NYK-1112 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
NYK-1341 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Dormant Projects 39
Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Discontinued Products 41
Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Featured News & Press Releases 42
Oct 25, 2016: OncoGenex Announces Positive Survival Results from Apatorsen Phase 2 Borealis-2 Trial in Metastatic Bladder Cancer 42
Mar 01, 2016: RedHill Biopharma Provides Update on RP101 42
Jan 20, 2016: OncoGenex Announces Update on Phase 2 Spruce Trial in Previously Untreated Metastatic Non-Small Cell Lung Cancer 43
Dec 09, 2015: OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion of Futility Analysis 44
Oct 29, 2015: Arno Therapeutics Data Demonstrate AR-12 as Novel Antifungal Drug Against Common Finger and Toenail Fungus, Onychomycosis 45
Oct 21, 2015: Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains 45
Sep 30, 2015: OncoGenex Announces Completion of Patient Enrollment in Borealis-2 Clinical Trial Evaluating Apatorsen in Relapsed or Refractory Metastatic Bladder Cancer 46
Sep 25, 2015: Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference 47
Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs 48
Sep 19, 2015: Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists Annual Exposition 49
Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015 50
Jun 01, 2015: OncoGenex Announces Data from Borealis-1 Trial Showing Clinical Benefit with Apatorsen in Metastatic Bladder Cancer 51
May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research 52
May 20, 2015: OncoGenex To Present Phase II Study Data On Apatorsen At ASCO 2015 Annual Meeting 53
May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12 53
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56

List of Tables
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Action, H2 2016 17
Number of Products by Stage and Route of Administration, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 21
Pipeline by Arno Therapeutics Inc, H2 2016 22
Pipeline by Nyken BV, H2 2016 23
Pipeline by Oncogenex Pharmaceuticals Inc, H2 2016 24
Pipeline by RESprotect GmbH, H2 2016 25
Dormant Projects, H2 2016 39
Dormant Projects (Contd..1), H2 2016 40
Discontinued Products, H2 2016 41

List of Figures
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Top 10 Indication, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Mechanism of Actions, H2 2016 16
Number of Products by Stage and Mechanism of Actions, H2 2016 16
Number of Products by Routes of Administration, H2 2016 18
Number of Products by Stage and Routes of Administration, H2 2016 18
Number of Products by Molecule Types, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 20

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *